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Abstract: The canonical nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
signaling pathway regulates central processes in mammalian cells and plays a fundamental role in 
the regulation of inflammation and immunity. Aberrant regulation of the activation of the 
transcription factor NF-κB is associated with severe diseases such as inflammatory bowel disease 
and arthritis. In the canonical pathway, the inhibitor IκB suppresses NF-κB’s transcriptional activity. 
NF-κB becomes active upon the degradation of IκB, a process that is, in turn, regulated by the β-
transducin repeat-containing protein (β-TrCP). β-TrCP has therefore been proposed as a promising 
pharmacological target in the development of novel therapeutic approaches to control NF-κB’s 
activity in diseases. This study explores the extent to which β-TrCP affects the dynamics of nuclear 
NF-κB using a computational model of canonical NF-κB signaling. The analysis predicts that β-TrCP 
influences the steady-state concentration of nuclear NF-κB, as well as changes characteristic 
dynamic properties of nuclear NF-κB, such as fold-change and the duration of its response to 
pathway stimulation. The results suggest that the modulation of β-TrCP has a high potential to 
regulate the transcriptional activity of NF-κB. 
Keywords: mathematical modelling; β-TrCP; NF-κB signaling; drug target; oscillation; fold-change; 
area under curve; ordinary differential equations 
 
1. Introduction 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling is involved in 
key cellular processes, such as proliferation, differentiation, and apoptosis, and plays a fundamental 
role in the regulation of inflammation and immunity [1,2]. NF-κB signaling is traditionally divided 
into two main pathway branches: The canonical and the non-canonical signaling pathway [3,4]. Here, 
we focus on the canonical pathway, in which the activity of the transcription factor NF-κB (p50/p65) 
is regulated by the abundance of the inhibitor IκBα, which sequesters NF-κB in the cytoplasm. If 
extracellular TNFα stimulates a cell, this signal is transduced intracellularly via the canonical 
pathway, resulting in the activation of the IκB kinase complex (IKK). Activated IKK phosphorylates 
IκB, which allows for the ubiquitination of IκB through a mechanism mediated by β-TrCP [4–6]. 
Ubiquitinated IκB is degraded by the proteasome, and, consequently, NF-κB is released from its 
complex with IκB. NF-κB can now translocate to the nucleus and regulate the transcription of target 
genes. 
Aberrations in the regulation of NF-κB activation are associated with severe diseases such as 
arthritis, Crohn’s disease, and autoimmune diseases. The underlying molecular mechanisms have 
not been clarified in all cases, since mutations are rarely found in components of this pathway [2,7]. 
Up-regulated NF-κB activity has been detected in various human cancers, potentially inducing the 
secretion of tumor-promoting cytokines and promoting cell resistance to anti-cancer therapies [2,8–
13]. These observations have made the molecular processes that regulate NF-κB activity, especially 
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the mechanisms involved in proteasomal IκB degradation, targets for the development of therapeutic 
approaches [2,3,14]. For instance, IKK inhibitors have been developed in hopes of achieving anti-
tumor and anti-inflammatory effects, but they have had only limited success so far [2,3,5,11]. 
Strategies of targeting the proteasome itself, with Bortezomib and other inhibitors, have been used in 
clinics, but such inhibitors are less specific and thus cause undesirable side effects [2,5,10,11,15,16]. 
Reducing side effects will likely require a more targeted approach within the NF-κB pathway 
[3,5,11,17]. 
β-TrCP's specificity as the central mediator of IκB degradation has attracted interest as 
promising pharmacological target that should be accompanied by fewer side effects [3,5,11,15,17,18]. 
Two paralogues of β-TrCP, β-TrCP1/FWD1 and β-TrCP2/HOS, exist in mammals. The paralogues are 
highly conserved within their functionally important F-box domain and β-transducin repeats but 
differ in their N-termini [19–21]. Generally, β-TrCP1/FWD1 and β-TrCP2/HOS are considered to be 
functionally redundant in the NF-κB signaling pathway [5,9,15,17,22]. This generally accepted notion 
of redundancy of the paralogues has been inferred from (i) their high degree of 77% sequence 
homology [21], (ii) their identical biochemical properties in vitro [15], (iii) their apparent reciprocal 
substitution in paralogue-specific small interfering RNA (siRNA)-mediated knock-down 
experiments [23], and (iv) the general viability of β-TrCP1/FWD1 knock-out mice [15,23,24].  
In addition to IκB, β-TrCP targets several other substrates for proteasomal degradation, such as 
Cdc25A, ATF, Per, and β-catenin [15,17]. In addition, several signaling pathways and regulatory 
molecules were shown to modulate the abundance of β-TrCP, including Wnt/β-catenin signaling 
[17,25,26], BMP/MAPK [27], Ras/MAPK [28], Src [29], JNK and Akt/PKB signaling [25,30], 
Ras/NORE1A [31], Vpu [32], and TRIM9 [22]. Thus, β-TrCP is in the center of a complex interaction 
network. We focus our study on β-TrCP's influence on NF-κB signaling and leave potential effects on 
the network to the discussion section. 
In our study, we explore what impact the modulation of β-TrCP-mediated IκB degradation has 
on the dynamics of nuclear NF-κB. To do so, we make use of a computational approach. Many 
computational models have been published to describe NF-κB signaling in order to investigate 
different biological questions [33–47], including the prediction of drug effects [48–51]. Despite the 
molecular elaborateness of several of these models, β-TrCP does not appear in any of them. We 
extend the detailed model of canonical NF-κB signaling established by Lipniacki et al. [34] by 
integrating β-TrCP-mediated IκB degradation and carry out a comprehensive analysis of β-TrCP’s 
regulatory impact on nuclear NF-κB concentration. 
2. Materials and Methods 
2.1. Modelling Canonical NF-κB Signaling 
The published model of the NF-κB pathway [34] consists of 14 ordinary differential equations 
(ODEs) and one conservation relation for NF-κB (Document S1). The model includes three activation 
forms of the IKK complex: A neutral form (IKKneutral), an active form (IKKactive), and an inactive 
form (IKKinactive). All three types are degraded (reaction 2, reaction 5, and reaction 6 in Figure 1), 
but only IKKneutral is produced de novo (reaction 1). TNF stimulation activates IKKneutral (reaction 
3). TNF is implemented into the model as a logical variable that is either set to 0 in the absence of a 
stimulus or to 1 if a stimulus is present (Document S1). Besides IKKneutral activation, TNF also 
promotes the inactivation of IKKactive (reaction 26). In addition, IKKactive inactivates itself in a TNF-
independent manner (reaction 4). IKKactive binds NF-κB-bound and unbound IκB (reaction 7 and 
reaction 9, respectively). IκB is degraded in an IKKactive-dependent (reaction 8 and reaction 10) and 
IKKactive-independent manner (reaction 15 and reaction 21). The IKKactive-dependent degradation 
of IκB via reaction 10 results in the dissociation of the IKKactive/IκB/NF-κB complex, liberating NF-
κB from its inhibitor. NF-κB can then translocate into the nucleus (reaction 11). In the nucleus, NF-
κB regulates the transcription of IκB-mRNA, A20-mRNA, and the control gene transcript “cgen-
mRNA” (reaction 18, reaction 22, and reaction 27, respectively). IκB-mRNA, A20-mRNA, and cgen-
mRNA are degraded via reaction 19, reaction 23, and reaction 28, respectively. IκB-mRNA and A20-
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mRNA are furthermore translated into their respective proteins (reaction 20 and reaction 24, 
respectively). A20 proteins promote the inactivation of IKKactive (reaction 26) and are degraded via 
reaction 25. IκB can either associate with NF-κB in the cytoplasm to form IκB/NF-κB complexes 
(reaction 14) or shuttle between the cytosolic and nuclear compartment (reaction 16 and reaction 17). 
Nuclear IκB (IκBnuc) associates with nuclear NF-κB (NF-κBnuc) to form nuclear IκBnuc/NF-κBnuc 
complexes (reaction 12). These nuclear complexes translocate from the nuclear to the cytosolic 
compartment (reaction 13). 
 
Figure 1. Reaction scheme underlying the model of canonical NF-κB signaling. Reactions and 
pathway components of the original model [34] are shown in black; reactions involving β-TrCP-
mediated IκB degradation are highlighted in red indicating model extensions. The nuclear species of 
the model are surrounded by the grey box. The numbers next to the arrows specify the number of the 
reaction. One-headed arrows denote reactions taking place in the indicated direction. Dashed arrows 
illustrate activations. Components in a complex are separated by slashes. The Methods Section 
provides additional explanations; Document S1 lists reaction rates and parameters of the model. cgen: 
Control gene; nuc: Nuclear. 
The model is used to analyze the impact of the regulation of β-TrCP-mediated IκB degradation 
on the dynamical properties of the nuclear NF-κB response to TNF stimulation. To this end, the model 
was extended such that the IKKactive-dependent degradation of IκB was regulated by β-TrCP 
(reaction 8 and reaction 10). 
2.2. Measures of Nuclear NF-κB Dynamics 
To quantitatively characterize the dynamics of species in ODE models, several measures have 
been introduced, reviewed in [52]. Here, we focused on two measures, signal duration and fold-
change [26,53–56], and defined them as follows: 
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These definitions can be applied to the wide range of different dynamical responses [26,53–55]. 
They do not require that the signal eventually returns to its initial steady state, and they are also 
suitable for oscillatory transitions. Numerically calculated steady states were used as initial 
conditions to simulate the continuous dynamics of model species over time to the final time point of 
630 min.  
2.3. Bifurcation Analysis 
We performed a bifurcation analysis by numerically calculating all steady states and their 
stability for distinct values of the bifurcation parameter β-TrCP, as described in [26] using 
Mathematica 10.0 (Wolfram Research, Champaign, IL, USA). Briefly, to calculate steady states, we set 
all time derivatives of the model to zero and solved the resulting system of algebraic equations for 
species concentrations, considering only non-negative real solutions. We determined steady-state 
stability by calculating the eigenvalues of the Jacobian matrix [57]. The Jacobian matrix is the matrix 
of all first-order partial derivatives of the ODEs, with respect to the species of the model. If the real 
parts of all eigenvalues are negative, the steady state is called stable. Otherwise, the steady state is 
called unstable. A Hopf bifurcation is detected if all eigenvalues of the Jacobian matrix have negative 
real parts, with the exception of one conjugate purely imaginary pair. The period length of oscillations 
is calculated by identifying the maximal frequency in the discrete Fourier transform of a simulated 
time course of nuclear NF-κB. 
3. Results 
3.1. Description of the Computational Model of Canonical NF-κB Signaling 
Our starting point to model NF-κB signaling was the detailed kinetic model published by 
Lipniacki and colleagues [34]. This model quantitatively describes the molecular processes that 
transduce an extracellular TNF signal into a change in nuclear NF-κB concentrations. The model 
accounts for transient TNF-dependent IKK activation, NF-κB-regulated target gene expression (cgen-
mRNA), and the inhibitory actions of IκB and A20 on NF-κB activation (Figure 1). The parameters used 
in the model have either been measured or good estimates have been derived to quantitatively describe 
the temporal changes observed in concentrations of pathway components in experiments [34]. 
The original model does not incorporate β-TrCP explicitly. To allow for the investigation of the 
potential influence of β-TrCP on nuclear NF-κB dynamics, we extended the existing model based on 
published experimental data. Experimental observations suggest that changes in the concentration 
of β-TrCP influence IκB degradation. The overexpression of β-TrCP reduced the concentration of IκB 
by enhancing its proteasomal degradation [19,21,58–60]. In contrast, the overexpression of a 
dominant negative mutant of β-TrCP inhibited the proteasomal degradation of IκB [19,21,58–60]. 
Furthermore, it was shown that the IKK-dependent phosphorylation of IκB is a prerequisite for the 
β-TrCP-mediated ubiquitination and degradation of IκB. Thus, we presumed β-TrCP to modulate 
the rates of both IKK-dependent IκB degradation reactions (reaction 8 and reaction 10, Figure 1) in 
our modelling approach. 
β-TrCP is thought to be expressed at low levels in cells [17], although absolute concentrations 
have not yet been published. Consequently, we varied the concentration of β-TrCP over a wide range 
in our model analyses to cover all possible conditions. The β-TrCP concentration of 1 nM is a special 
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case. In that situation, the extended model and the original model published by Lipniacki and 
colleagues behave identically. Figure 2A shows the transient dynamics of nuclear NF-κB (NF-κBnuc) 
upon TNF stimulation, assuming a β-TrCP concentration of 1 nM. Nuclear NF-κB dynamics was, in 
this case, characterized by a transient increase in the nuclear NF-κB concentration to about 56 nM in 
the first 90 min after TNF stimulation (first peak), followed by four minor peaks with decreasing 
amplitudes indicating damped oscillations. 
Figure 2. Impact of β-TrCP abundance on the transient dynamics of nuclear NF-κB upon TNF 
stimulation. (A–C) Simulations of the dynamics of nuclear NF-κB (NF-κBnuc) upon TNF stimulation 
are shown assuming (A) 1 nM β-TrCP, (B) 10–2 nM β-TrCP, and (C) 10–4 nM β-TrCP. (D) Dependence 
of the fold-change of nuclear NF-κB upon TNF stimulation assuming β-TrCP concentrations between 
5·× 10–5 and 2 nM. (E) Influence of β-TrCP abundance on signal duration of nuclear NF-κB dynamics 
upon TNF stimulation assuming β-TrCP concentrations between 5·× 10–5 and 2 nM. 
3.2. β-TrCP Abundance Influences the Transient Dynamics of Nuclear NF-κB upon TNF Stimulation 
Simulations (Figure 2A–C, Model S1) showed that the dynamics of nuclear NF-κB upon TNF 
stimulation differ when concentrations of β-TrCP change. Choosing values of 10–4, 10–2, and 1 nM 
(Figure 2A–C) showed that higher β-TrCP concentrations led to larger maxima of the first peak of 
nuclear NF-κB concentration (1.4, 40, and 56 nM, respectively). The maxima of the consecutive peaks 
were also affected. 
Different features of nuclear NF-κB dynamics have been proposed to correlate with the 
responses of NF-κB target genes on expression levels [37,61], such as the magnitude of nuclear NF-
κB [56,62–64], the number of peaks (duration of oscillations) [62,63], and the inter-peak intervals 
(period) [46,65]. To quantify these features, different measures have been proposed, such as the 
amplitude of the first peak [62–64,66,67], maximal fold-change [43,56,68,69], the accumulative 
response (area under curve) [48,56,67–69], steady state concentration upon TNF stimulation [66], the 
timing of the first peak [62–64,66,67], length of inter-peak intervals [62,65,66], and duration of the 
oscillations [62,63,66]. Here, we focused on two established measures, fold-change and signal 
duration, which are defined in the Methods Section. Fold-change can be interpreted as a measure of 
the magnitude of NF-κB activation, while signal duration characterizes temporal aspects of the NF-
κB response to TNF stimulation. 
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To analyze the influence of β-TrCP abundance on the dynamics of nuclear NF-κB, we systematically 
calculated the fold-change of nuclear NF-κB dynamics upon TNF stimulation, assuming β-TrCP 
concentrations between 5·× 10–5 and 2 nM (Figure 2D). The simulations demonstrated that increasing β-
TrCP concentrations increased the fold-change of nuclear NF-κB from approximately 1 to 122 fold (Figure 
2D). This analysis indicates that β-TrCP concentrations below a critical level (about 10–4 nM) impede the 
response of nuclear NF-κB to TNF stimulation (e.g., compare with Figure 2C). 
Calculations showed that the signal duration of nuclear NF-κB upon TNF stimulation also 
depends on β-TrCP concentration, but, in this case, the relationship was biphasic (Figure 2E). 
Concentrations of β-TrCP up to approximately 0.01 nM caused the signal duration to rise from about 
80 to 190 min. Beyond that critical β-TrCP concentration, however, the signal duration dropped to 
about 80 min again (Figure 2E). Simulations indicated that this change in signal duration reflects a 
change in the dampening of nuclear NF-κB oscillations (Figure 2A–C). The closer the β-TrCP 
concentration approached the value of 0.01 nM, the less dampened nuclear NF-κB dynamics was and, 
as a result, the longer the NF-κB response to TNF stimulation lasted. 
We additionally analyzed β-TrCP’s influence on the area under the curve, signal amplitude 
(amplitude of 1st peak), and signaling time, which represent three additional established measures 
(Figure S1). We found that the area under the curve and signal amplitude increased with increasing 
concentrations of β-TrCP, similar to fold-change. Signaling time showed a biphasic relation with β-
TrCP, similar to signal duration. 
To summarize, β-TrCP abundance affects all investigated measures—the fold-change and 
duration of the nuclear NF-κB signal, in particular. The analysis also indicates that a critical minimal 
β-TrCP concentration is necessary to observe a response of nuclear NF-κB to TNF stimulation and 
that intermediate β-TrCP concentrations of about 0.01 nM prolong NF-κB oscillations. 
3.3. β-TrCP Abundance Affects Long-Term Dynamical Behavior of Nuclear NF-κB 
The previous analysis showed that the abundance of β-TrCP influences several features that are 
characteristic of the transient dynamics of nuclear NF-κB after cellular stimulation by TNF. Next, we 
investigated its influence on long-term dynamics. Figure 3A shows how long-term dynamics are 
affected by concentrations of β-TrCP between 5·× 10–5 and 2 nM. Raising the concentration of β-TrCP 
increased the steady-state concentration of nuclear NF-κB reached after TNF stimulation. The more 
β-TrCP that was available, the more IκB was ubiquitinated and degraded, which resulted in the 
release of NF-κB from IκB/NF-κB complexes and accumulation of NF-κB in the nucleus. This 
accumulation had an upper limit of about 16.7 nM, which was reached at β-TrCP concentrations of 
about 1 nM; higher β-TrCP levels led to very little further change in nuclear NF-κB (Figure 3A). Below 
a certain concentration (about 10-4 nM), concentrations of β-TrCP also had very little impact on the 
stimulated steady-state concentration of nuclear NF-κB. In these cases, the stimulated steady-state 
concentration was approximately the same as the steady-state concentration of nuclear NF-κB in the 
absence of TNF stimulation (about 0.46 nM). 
 
Figure 3. Bifurcation analysis of the stimulated steady state of nuclear NF-κB with respect to β-TrCP 
abundance. (A) β-TrCP abundance influences the stimulated steady-state concentration of nuclear NF-
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κB and the stability of this steady state. The thick red lines denote stable stimulated steady states of 
nuclear NF-κB (NF-κBnuc). The grey dashed line denotes unstable stimulated steady states. The dotted 
lines show minimal and maximal values of the amplitude of stable limit cycle oscillations occurring 
between the two Hopf bifurcation (HB) points at approximately 5.5·× 10–3 and 1.6·× 10–2 nM. (B) 
Calculated period length of the limit cycle oscillations simulated for selected values of β-TrCP 
concentrations between the Hopf bifurcation points (indicated by dashed grey lines). The period hardly 
changes for the considered values of β-TrCP. 
The abundance of β-TrCP also influences the stability of the stimulated steady state. A 
bifurcation analysis revealed two Hopf bifurcation (HB) points, at approximately 5.5·× 10–3 and 1.6·× 
10–2 nM (Figure 3A). Between these two HB points, the stimulated steady state was unstable (Figure 
3A; dashed line) and stable limit cycle oscillations of nuclear NF-κB existed. The oscillations had 
period lengths within a narrow range, lasting from 100 to 112 min, depending on the value of β-TrCP 
concentration (Figure 3B). The minimal and maximal values of the amplitude of nuclear NF-κB 
oscillations, however, varied widely for β-TrCP concentrations between the two HB points (Figure 
3A; dotted lines). 
These results show that the regulation of β-TrCP abundance can affect both the stimulated 
steady-state concentration of nuclear NF-κB and its stability. Therefore, the abundance of β-TrCP 
potentially determines whether damped oscillations or sustained limit-cycle oscillations are observed 
upon TNF stimulation. 
4. Discussion 
This investigation was motivated by recent interest in the molecule β-TrCP as a potential 
therapeutic target in modulating cellular signal transduction involving NF-κB. Aberrations in NF-κB 
signaling are well documented in many types of cancer and other diseases, and a number of 
approaches have been developed to target components of the pathway. Finding a way to control the 
concentration of NF-κB in the nucleus has been central to this idea. Attempts to target regulators of 
NF-κB have led to advances in clinical treatment, e.g., using Bortezomib, but were limited in their 
success due to non-specific effects—a situation that has stimulated interest in pathway components 
such as β-TrCP [3,5,11,17]. Our aim was to explore and quantify to what extent β-TrCP could regulate 
nuclear NF-κB. 
We demonstrated that the regulation of β-TrCP-mediated IκB degradation can affect the steady-
state concentration of nuclear NF-κB, as well as many characteristics of the dynamics of nuclear NF-
κB upon TNF stimulation (Figure 2, Figure 3, Figure S1). This is in accordance with the general 
opinion that the control of β-TrCP expression level is a very important factor in the regulation of NF-
κB signaling [5,17,19,25]. Our model analysis predicts that enhancing the β-TrCP-mediated 
degradation of IκB increases the steady-state concentration of nuclear NF-κB (Figure 3A). This 
prediction agrees with many experimental observations based on the overexpression of β-TrCP in 
various mammalian cell types [8,19,21,25,30,58,60]. It also corroborates the hypothesis that 
upregulated β-TrCP, which is frequently observed in various human cancers, supports tumorigenesis 
by activating NF-κB-dependent anti-apoptotic pathways [5,8,11,17]. Our model analysis further 
predicts that β-TrCP abundance affects transient nuclear NF-κB dynamics in response to TNF 
stimulation of the pathway. Our results were confirmed in two other NF-κB pathway models [43,65] 
that differ in their model structure and parametrization from our model (Figure S2), demonstrating 
the robustness of our predictions. 
Negative feedback mechanisms, such as those which occur via IκB and A20, can create 
oscillations in the dynamics of the pathway components [70–72]. Nuclear NF-κB concentrations, for 
example, have been observed to exhibit sequences of peaks when cells are stimulated by TNFα under 
certain experimental conditions [33,62,63,65,73–75]. Whether nuclear NF-κB exhibits oscillations 
under all cellular conditions is a subject of ongoing investigation, as is their detailed role in the control 
of the expression of target genes and their subsequent physiological effects [43,46,62,63,73,76–80]. 
One proposal has been that the number, period, and/or amplitude of oscillation peaks determine the 
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functional consequences of NF-κB signaling [46,62,63,79–81]. The cited biological literature usually 
defines oscillations as consecutive sequences of three or more concentration peaks. Depending on the 
total number of observed peaks, the oscillations may be additionally categorized into damped or 
sustained oscillations. However, from the data that is available, it is difficult to draw conclusions 
about the existence of sustained oscillations (i.e., limit cycle oscillations in mathematical terms). Our 
analysis with respect to β-TrCP revealed two Hopf bifurcation points, implying that β-TrCP 
abundance may determine whether oscillations of the nuclear NF-κB concentration that occur upon 
TNF stimulation are damped or sustained. The period length of the simulated limit cycle oscillations 
remained almost constant at approximately 100 to 110 minutes for different β-TrCP concentrations 
(Figure 3B), which is in agreement with inter-peak intervals that have been experimentally measured 
in mouse fibroblasts [33,62,63,73–75] and human cells [46,78]. While this period length remains 
almost constant, the amplitude of the limit cycle oscillations is strongly dependent on the 
concentrations of β-TrCP (Figure 3A). We thus conclude that β-TrCP abundance influences all of the 
measures of nuclear NF-κB dynamics that are under discussion with the exception of the length of 
the oscillation period, and that, in consequence, this probably has an influence on the expression of 
NF-κB target genes. 
Our analyses predict that modulating β-TrCP-dependent IκB degradation would have a strong 
regulatory impact on the dynamics of nuclear NF-κB for a broad range of cellular β-TrCP 
concentrations. However, potential drugs will likely change β-TrCP’s activity only transiently 
depending on their pharmacokinetic properties—a point we have not yet addressed. We thus 
simulated different possible kinetic profiles of drug action and showed that the response dynamics 
of nuclear NF-κB upon TNF stimulation can change in the presence of the drug (Figure S3A–E). The 
extent of the drug’s effect depends on the particular specifics of the pharmacokinetics as well as the 
concentration of β-TrCP. 
Whether β-TrCP could represent a useful pharmacological target has been discussed at several 
occasions [3,5,11,15,17,18]. A central counter-argument against such an approach has been that β-
TrCP recognizes several other signaling molecules in addition to IκB. The regulation of multiple 
substrates by β-TrCP suggests that targeting β-TrCP could cause undesirable side effects outside of 
NF-κB signaling. An example is β-catenin, the transcriptional regulator in Wnt/β-catenin signaling 
[12,13,15,17,82,83]. β-Catenin was shown to directly bind to the p65 and p50 subunits of NF-κB [84–
87]. In this way, Wnt/β-Catenin signaling may create additional complexity to the regulation of NF-
κB dynamics by β-TrCP. To investigate this mechanism of regulation, a computational model of 
crosstalk between NF-κB and Wnt/β-catenin signaling is needed.  
We argue here that targeting β-TrCP may still be sensible despite its multiple substrates. 
Essentially, β-TrCP’s activity can be changed by the control of its availability for its substrate, i.e., its 
abundance, and/or by the modulation of its physicochemical properties, i.e., association and 
dissociation rates of β-TrCP and its substrate. We argue that if a potential drug does not affect β-
TrCP’s abundance but does affect its binding to IκB, it may be feasible to achieve NF-κB pathway 
specificity. To support this idea, we simulated a kinetic profile of drug action, assuming that the drug 
inhibits the activity of β-TrCP, by reducing the rate of IκB binding. The simulations demonstrate that 
the influence of the drug on nuclear NF-κB dynamics (Figure S3F) is identical to that of a drug, which 
modulates β-TrCP’s abundance (Figure S3B(ii)). Importantly, the drug that inhibits IκB binding does 
not change β-TrCP’s abundance and may consequently preclude effects on other β-TrCP substrates. 
Small molecules that affect the association of β-TrCP with IκB have already been identified and are 
being used in experimental settings, including the small molecule inhibitor of IκBα ubiquitination 
(GS143) [88,89]. GS143 appears to be specific to the NF-κB pathway [88,89]; at least, it does not 
simultaneously promote the activation of Wnt/β-catenin signaling. 
In summary, the results from our computational model analyses confirm that targeting β-TrCP 
has a great potential to regulate nuclear NF-κB responses in various ways. We conclude that the 
modulation of β-TrCP is a useful tool to modify pathway dynamics and offers a productive strategy 
to investigate their impact on target gene expression. How this principle can be applied in clinical 
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treatments will depend on further research to determine which characteristics of the nuclear NF-κB 
dynamics are most crucial in a particular pathophysiological condition. 
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Figure_S2.pdf provides confirmation of our results in two other NF-κB pathway models. Figure S3: 
Figure_S3.pdf shows the influence of a kinetic profile of a drug targeting β-TrCP. Model S1: The Mathematica 
notebook NFkB-Model_UBenary_etal.nb provides the ready-to-use code to reproduce Figure 2A. The code can 
be easily extended to reproduce any figures and data of this manuscript.  
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